Doliver Advisors LP Sells 261 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Doliver Advisors LP lessened its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,534 shares of the medical equipment provider’s stock after selling 261 shares during the quarter. Doliver Advisors LP’s holdings in Intuitive Surgical were worth $1,736,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the stock. One Wealth Management Investment & Advisory Services LLC lifted its position in shares of Intuitive Surgical by 3.4% during the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock valued at $310,000 after purchasing an additional 23 shares in the last quarter. Indiana Trust & Investment Management CO increased its position in shares of Intuitive Surgical by 5.3% during the second quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock valued at $222,000 after acquiring an additional 25 shares during the last quarter. Hoxton Planning & Management LLC lifted its holdings in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock worth $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network boosted its position in Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock worth $443,000 after purchasing an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. grew its stake in Intuitive Surgical by 2.3% in the 2nd quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock valued at $516,000 after purchasing an additional 26 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ISRG shares. Redburn Atlantic upgraded shares of Intuitive Surgical from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $380.00 to $510.00 in a report on Friday, August 2nd. Barclays upped their price objective on Intuitive Surgical from $430.00 to $490.00 and gave the company an “overweight” rating in a research note on Thursday, July 18th. Evercore ISI upped their price target on Intuitive Surgical from $410.00 to $475.00 and gave the company an “in-line” rating in a research report on Tuesday. Truist Financial boosted their price objective on Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a research note on Tuesday, July 16th. Finally, Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $449.70.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now directly owns 3,001 shares in the company, valued at $1,461,006.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Robert Desantis sold 376 shares of the stock in a transaction dated Monday, July 29th. The stock was sold at an average price of $446.60, for a total transaction of $167,921.60. Following the completion of the sale, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,458,979.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Henry L. Charlton sold 40,243 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $486.84, for a total value of $19,591,902.12. Following the sale, the senior vice president now directly owns 3,001 shares of the company’s stock, valued at approximately $1,461,006.84. The disclosure for this sale can be found here. In the last three months, insiders sold 53,120 shares of company stock worth $25,528,753. 0.90% of the stock is currently owned by corporate insiders.

Intuitive Surgical Trading Up 0.4 %

Shares of ISRG opened at $486.62 on Thursday. The stock has a 50-day moving average price of $474.88 and a 200-day moving average price of $430.58. The company has a market cap of $172.60 billion, a PE ratio of 87.84, a price-to-earnings-growth ratio of 5.39 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. During the same period in the previous year, the business earned $1.18 earnings per share. The firm’s quarterly revenue was up 14.5% compared to the same quarter last year. As a group, analysts predict that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.